Home > Insider Trading > Filing (0001576885-25-000037)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1576885	Acumen Pharmaceuticals Inc.	ABOS	Biological Products, (No Disgnostic Substances) (2836)	364108129

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1790214	Matt Zuga	C/O Acumen Pharmaceuticals, Inc. 1210-1220 Washington Street, Suite 210 Newton MA 02465	Cfo & Chief Business Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2025-01-21	4,364	$1.60	260,646	No	4	S	Direct
Common Stock	Disposition	2025-01-23	28,902	$1.72	231,744	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Footnotes

Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.5800 to $1.6100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Represents the number of shares sold by the Reporting Person in connection with the vesting of RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 24, 2024.
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.6705 to $1.7699. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.